Biblio

Found 5 results

Filters: Keyword is Opiate Substitution Treatment [Clear All Filters]

2023

Jones KFitzgerald, Jacob MO'Reilly, Spetz J, Hailer L, Tierney M. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach. J Nurs Scholarsh. 2023 ;55(3):655-664.

2022

Nguyen T, Andraka-Christou B, Arnaudo C, W Bradford D, Simon K, Spetz J. Analysis of US County Characteristics and Clinicians With Waivers to Prescribe Buprenorphine After Changes in Federal Education Requirements. JAMA Netw Open. 2022 ;5(10):e2237912.

Andraka-Christou B, Gordon AJ, Spetz J, Totaram R, Golan M, Randall-Kosich O, Harrison J, Calder S, Kertesz SG, Stein BD. Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing. J Subst Abuse Treat. 2022 ;138:108715.

Spetz J, Hailer L, Gay C, Tierney M, Schmidt LA, Phoenix B, Chapman SA. Buprenorphine Treatment: Advanced Practice Nurses Add Capacity. Health Aff (Millwood). 2022 ;41(9):1231-1237.

Spetz J, Hailer L, Gay C, Tierney M, Schmidt L, Phoenix B, Chapman S. Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements. JAMA Netw Open. 2022 ;5(5):e225996.